Lv5
1160 积分 2023-02-19 加入
European Academy of Neurology/Movement Disorder Society ‐ European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies
8天前
已完结
Progress in Disease-Modifying Therapies for Parkinson's Disease
8天前
已完结
Genetics of Parkinson's Disease: From Causes to Treatment
8天前
已完结
Disease-Modifying Therapies in Parkinson’s Disease
8天前
已关闭
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
1个月前
已完结
Efficacy and Safety of Ravulizumab in IgA Nephropathy
2个月前
已完结
Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy
2个月前
已完结
Cancer incidence and mortality in China, 2022
3个月前
已完结
The evolving landscape of RAS-targeted therapies
3个月前
已完结
Response and Resistance to RAS Inhibition in Cancer
3个月前
已完结
皖公网安备34019202002308
